Described inter alia are compounds according to formula (I): or a pharmaceutically acceptable salt thereof, and uses in methods for the modulation of flap endonuclease 1 (FEN1), Xeroderma Pigmentosum Complementation Group G protein (XPG), Exonuclease 1 (EXO1) and/or GEN1. ##STR00001##

This invention relates to novel Quinazoline-2,4(1H,3H)-dione derivatives of Formula (I): ##STR00001## and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have meanings given in the description.

This invention relates to novel Quinazoline-2,4(1H,3H)-dione derivatives of Formula (I): ##STR00001## and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have meanings given in the description.

Disclosed in the present invention is a triketone compound which has a structure shown in Formula (I). Also disclosed in the present invention is a method for preparing the triketone compound having a structure as shown by Formula (I), which comprise that under the rearrangement reaction conditions, the compound having a structure as shown by Formula (II) is contacted with a catalyst in the presence of a base and a solvent. Further disclosed in the present invention is the use of a triketone compound having a structure as shown by Formula (I) in preventing and controlling weeds. Said triketone compound having a structure as shown by formula (I) in the present invention has the effect of preventing and controlling weeds, in particular having an excellent effect on preventing and controlling broadleaved weeds and/or gramineae weeds.

Disclosed in the present invention is a triketone compound which has a structure shown in Formula (I). Also disclosed in the present invention is a method for preparing the triketone compound having a structure as shown by Formula (I), which comprise that under the rearrangement reaction conditions, the compound having a structure as shown by Formula (II) is contacted with a catalyst in the presence of a base and a solvent. Further disclosed in the present invention is the use of a triketone compound having a structure as shown by Formula (I) in preventing and controlling weeds. Said triketone compound having a structure as shown by formula (I) in the present invention has the effect of preventing and controlling weeds, in particular having an excellent effect on preventing and controlling broadleaved weeds and/or gramineae weeds.

The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I):

##STR00001##

[wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I):

##STR00001##

[wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

The present invention relates to a compound, or a dimer or a pharmaceutically acceptable salt or solvate of said compound or dimer, for use in a method for the treatment of a disease, disorder or condition caused by an RNA virus, said compound having the general structure shown in Formula (I).

##STR00001##

The present invention relates to a compound, or a dimer or a pharmaceutically acceptable salt or solvate of said compound or dimer, for use in a method for the treatment of a disease, disorder or condition caused by an RNA virus, said compound having the general structure shown in Formula (I).

##STR00001##

Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): ##STR00001## wherein Ar, R.sub.1-R.sub.6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.